Tamara Etto News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ --Antengene recently unveiled a new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help Antengene to attract more top talents, and further accelerate its expansion in the APAC region as well as its committed efforts to bring high quality and affordable innovative medicines to patients with life-threatening conditions including hematologic malignancies and solid tumors in Asia Pacif...

XPOVIO (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in tripleclass refractory R/R MM. XPOVIO is the first of a new class of SINE medicines to be made available to Australian patients with penta-refractory R/R MM on the Pharmaceutical Benefits Scheme (PBS). SHANGHAI and HONG KONG, Sept. 1, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-...